Compare ProShares Ultra Gold ETF (UGL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Gold ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 14.1× ProShares Ultra Gold ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Gold ETF for 23 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UGL | XBI | |
|---|---|---|
Market Cap | $716.59M | $10.11B |
Volume | 2,592,878 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $85.62 | $169.55 |
52-Week Low | $42.79 | $104.99 |
Typical Hold Time | 23 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGL is trading at $46.45, up 4.55% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key resistance at $46. Current financial ratios are unavailable, limiting fundamental assessment. Recent gold market volatility driven by Treasury yields and Fed policy expectations creates uncertainty for gold-related equities.
The outlook remains cautious given technical weakness and macroeconomic pressures on gold prices. Investment opportunity exists for contrarian investors if gold regains momentum, but risks include persistent rate hike expectations and dollar strength. Stock-specific fundamentals require verification through SEC filings for proper valuation assessment.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
